Published on
Apr 14, 2025
FDA Sets Review Date for Chronic Lung Disease Therapy Brensocatib
The FDA has accepted Insmed Incorporated’s new drug application (NDA) for brensocatib to treat patients with non–cystic fibrosis bronchiectasis. Regulators have granted priority review and set a target action date of August 12, 2025, under the Prescription …
Source:
Total Pharmacy
-
Pending
.jpg)
